NSE filing, NSE: SAKAR. Summary written from the filing by ALFA Finder's alert engine.
Sakar Healthcare Ltd: key numbers
- Share price
- ₹944.80
- Market cap
- ₹2,102 Cr
- Revenue (annual)
- ₹251.7 Cr
- Net profit (annual)
- ₹30.48 Cr
- P/E (TTM)
- 49.0×Sector 45.9×
- Promoter holding
- 51.70%-0.82% QoQ
- FII holding
- 12.34%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sakar Healthcare Ltd
All →Sakar Healthcare Earnings Call Transcript: Key Takeaways
Sakar Healthcare delivered exceptional growth as its oncology segment scales, with EBITDA doubling and margins expanding significantly due to product-mix shifts. Management is pivoting from a non-oncology focus to high-margin oncology formulations and APIs.
- Call
- Guides 35% growth
Sakar Healthcare Investor Presentation: Key Takeaways
Q2FY27 consolidated revenue Rs87.4 Cr (+52% YoY), EBITDA Rs24.4 Cr (28% margin), PAT Rs11.3 Cr (+149%); pitch centres on oncology integration.
Sakar Healthcare Results Update
Sakar Healthcare reported Q2 FY27 revenue of ₹87.42 Cr and PAT of ₹11.31 Cr, up 149% YoY. EBITDA rose 114% to ₹24.35 Cr on strong oncology approvals and commercial supply commencement.
Sakar Healthcare Q2 FY27 Results: Net Profit ₹11.3 Cr, Up 151.1% YoY
Sakar Healthcare Ltd reported revenue from operations of ₹87.4 Cr (+51.7% YoY) and net profit of ₹11.3 Cr (+151.1% YoY) for Q2 FY27.
- Key figure
- Net profit ₹11.3 Cr · +151.1% YoY
Sakar Healthcare Board Meeting Date
Sakar Healthcare has scheduled a board meeting for October 23, 2026, to approve its unaudited quarterly financial results for the period ended September 2026.
Sakar Healthcare Business Update
Sakar Healthcare says its oncology export model is expanding, with 22 Marketing Authorizations granted and commercial supply starting from its EU GMP site. No monetary value stated.
Other board meeting date announcements
All →Prism Medico and Pharmacy Board Meeting Date
Prism Medico and Pharmacy will hold a board meeting on November 5, 2026 to consider unaudited standalone half-yearly financial results for the period ended September 2026. The trading window closes from October 1 until November 7, 2026.
Fredun Pharmaceuticals Board Meeting Date
Fredun Pharmaceuticals will hold a board meeting on 05 November 2026 to consider half-year results. Trading window stays closed until 48 hours after results.
Capricorn Systems Global Solutions Board Meeting Date
Capricorn Systems Global Solutions Ltd notified BSE of a board meeting on 07 November 2026 to consider unaudited financial results for the quarter and half-year ended 30 September 2026. The filing is an advance notice with no results figures attached.
Ganesh Green Bharat Board Meeting Date
Ganesh Green Bharat will hold a board meeting on 5 November 2026 to consider unaudited half-yearly results. Trading window stays closed until 10 November 2026.
Yogi Board Meeting Date
YOGI Ltd schedules a board meeting on 5 November 2026 for Q2 results and a director regularisation. Trading window closes 1 October to 7 November 2026.
Superhouse Board Meeting Date
Superhouse Limited will hold a board meeting on 14-Nov-2026 to consider unaudited standalone and consolidated half-yearly results for September 2026. Trading window closes from 01-Oct-2026 until 17-Nov-2026.